Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
MARKHAM, Ontario, March 31, 2021 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna”) (TSX: SIA) announced today that the Toronto...
Company Continues International Growth To Serve Untapped Market of Consumers Without Access to Affordable, Convenient Oral CareNASHVILLE, Tenn., March 31, 2021...
Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48%...
Data-Driven Research Presented at Academy of Managed Care Pharmacy (AMCP), ISPOR Annual Meeting and Key Spring Conferences Powered by Inovalon’s...
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the...
- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds--Reported clinical data for anti-CD137 and two anti-CTLA-4...
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology BridgeBio, through...
Company announcement – No. 18/ 2021 Total number of shares and voting rights in Zealand Pharma at March 31, 2021...
TORONTO and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the...
Appoints George Steinbrenner IV to its Board of DirectorsCHICAGO, March 31, 2021 (GLOBE NEWSWIRE) -- Wesana Health Inc. (“Wesana” or...
Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold Conference Call Today at 8:00am Eastern Time NEW YORK, March...
- BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than...
FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogelProof-of-concept trial will evaluate...
BARRIE, Ontario, March 31, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or...
Divestment of Natural Colors to EQT closed as of March 31, 2021 Chr. Hansen Holding A/S and EQT today announced...
Notice of Allowance Grants Protection for Deriving Exosomes from Brown AdipocytesMELVILLE, N.Y., March 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies,...
MISSISSAUGA, Ontario, March 31, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF)( “Microbix®” or the Company”), a...
- New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies - Adds Magnetar Group, Yonjin Ventures...
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (OTCQX: BTTR) (the “Company” or “Better Choice”), an...